This is the case with CCAT-1, a superenhancer of MYC in colon cancer, which transcription is highly sensitive to bromodomain inhibitors in vitro [57].Thus, it becomes clear that future biomarker studies will have to focus on lncRNAs to tailor individual treatments and to identify and overcome therapeutic resistance. The gene discussed is MYC; the disease is malignant colon neoplasm.